+1-888-308-5802      . .

Bayer and Atara partner to develop treatment options for solid tumors

Author : Pankaj Singh | Published Date : 2020-12-07 

Bayer and Atara partner to develop treatment options for solid tumors

Bayer AG, a Germany-based leading pharmaceutical and life science company, has recently announced a strategic collaboration with an American biotechnology company Atara Biotherapeutics Inc. Sources with relevant information stated that the two company have teamed up to research, develop and manufacture mesothelin-directed CAR T-cell therapies for treating solid tumors.

For those uninitiated, Atara Biotherapeutics is one of the few prominent companies in T-cell immunotherapy, possessing advanced CAR T technologies as well as allogeneic cell manufacturing processes. Atara’s technology is reportedly based on EVB (Epstein-Barr Virus) T-cell platform, which is integrated with CAR T solutions and primarily targets mesothelin in order to enhance durability, safety, persistence and efficacy of response.

As per the agreement, the duo will develop an armored allogenic T-cell immunotherapy called ATA3271, alongside an autologous version ATA2271 for treatment of high mesothelin-expressing tumors including non-small-cell lung cancer and malignant pleural mesothelioma. Atara will lead Investigational New Drug (IND)-based research and development for ATA3271, while Bayer will focus on submitting the IND and its subsequent clinical development, sources claimed.

Wolfram Carius, Head of Cell & Gene Therapy Unit at Bayer, was reported saying that the recent collaboration reflects Bayer’s efforts in cell & gene therapy. He added that the company is looking forward to working with Atara in order to develop advanced CAR T-cell therapies for individuals with difficult-to-treat cancers.

President and CEO at Atara, Pascal Touchon mentioned in a comment that the partnership will help in boosting the development of mesothelin targeted CAR T-cell therapies for various types of solid tumors. He added that the company will benefit from Bayer’s proven track record in oncology as well as in cell and gene therapy.

If reports are to be believed, Atara will be responsible for the ongoing phase 1 study of ATA2271, for which an IND filing as already been accepted. Meanwhile, Bayer will gain non-exclusive right to negotiate a licensee for other CAR T product candidates of Atara.

Source Credits –

https://www.businesswire.com/news/home/20201206005066/en/Bayer-and-Atara-Biotherapeutics-Enter-Strategic-Collaboration-for-Mesothelin-Targeted-CAR-T-cell-Therapies-for-Solid-Tumors

About Author

Pankaj Singh . .

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Bayers new CEO initiates management job cuts to accelerate decision-making

Bayers new CEO initiates management job cuts to accelerate decision-making

Published Date: 2023-09-15         Author: Pankaj Singh

Bayer newly appointed CEO, Bill Anderson, has reportedly unveiled plans to streamline the companys management structure in a bid to expedite decision-making processes. This marks the first step in a broader effort to transform the embattled German company, which has been under pressure from inv... Read More>>

Smurfit Kappa in Merger Talks with WestRock worth $19 Billion

Smurfit Kappa in Merger Talks with WestRock worth $19 Billion

Published Date: 2023-09-08         Author: Pankaj Singh

Smurfit Kappa, a prominent player in the packaging industry, is reportedly engaged in merger discussions with its US counterpart, WestRock. This prospective merger has the potential to create a cardboard box-making powerhouse boasting a market value approaching $19 billion (€17.8 billion). Furt... Read More>>

RBC plans job cuts to take on anticipated economic softening

RBC plans job cuts to take on anticipated economic softening

Published Date: 2023-08-25         Author: Pankaj Singh

The Royal Bank of Canada is reportedly planning to reduce its workforce by approximately 1,800 jobs as part of cost-cutting measures, on account of the anticipated upcoming economic landscape. This decision comes after the country's largest bank surpassed analysts' predictions for the third ... Read More>>

© 2024 Fractovia. All Rights Reserved